Georgina V Long Selected Research

dabrafenib

5/2024	Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma.
5/2024	Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
11/2023	Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
1/2023	Adjuvant therapy for stage II melanoma: the need for further studies.
1/2023	Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.
1/2022	Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage III melanoma.
1/2022	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
1/2022	Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
1/2021	Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
1/2021	Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Georgina V Long Research Topics

Disease

375	Melanoma (Melanoma, Malignant) 06/2024 - 04/2011
146	Neoplasms (Cancer) 04/2024 - 03/2012
74	Neoplasm Metastasis (Metastasis) 05/2024 - 12/2012
29	Brain Neoplasms (Brain Tumor) 01/2024 - 03/2012
25	Disease Progression 11/2023 - 11/2012
11	Fever (Fevers) 01/2021 - 11/2012
6	Colitis 01/2024 - 01/2019
6	Lymphatic Metastasis 01/2022 - 01/2019
6	Autoimmune Diseases (Autoimmune Disease) 11/2021 - 02/2016
5	Uveal melanoma 12/2023 - 01/2020
5	Inflammation (Inflammations) 01/2023 - 01/2017
5	Body Weight (Weight, Body) 10/2019 - 01/2015
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2015 - 04/2014
4	Pneumonia (Pneumonitis) 01/2022 - 01/2017
4	Fatigue 01/2019 - 01/2015
3	Skin Neoplasms (Skin Cancer) 02/2024 - 04/2014
3	Pain (Aches) 02/2024 - 05/2015
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 01/2021
3	Hypophysitis 01/2023 - 08/2014
3	Encephalitis (Encephalitis, Rasmussen) 12/2022 - 01/2019
3	Glioma (Gliomas) 12/2022 - 01/2020
3	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2019
3	Neutropenia 01/2021 - 11/2012
3	Nevus (Nevi) 01/2019 - 07/2012
2	Sarcoma (Soft Tissue Sarcoma) 06/2024 - 10/2014
2	Squamous Cell Carcinoma of Head and Neck 10/2023 - 01/2019
2	Overweight 01/2023 - 01/2018
2	Hypertension (High Blood Pressure) 11/2022 - 01/2017
2	Exanthema (Rash) 11/2022 - 01/2019
2	Thyrotoxicosis 01/2022 - 01/2021
2	COVID-19 01/2022 - 01/2021
2	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2022
2	Hypothyroidism 01/2022 - 01/2021

Drug/Important Bio-Agent (IBA)

82	Immune Checkpoint InhibitorsIBA 04/2024 - 02/2015
63	dabrafenibIBA 05/2024 - 01/2012
61	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2024 - 11/2012
59	pembrolizumabIBA 03/2024 - 06/2015
57	IpilimumabIBA 01/2024 - 01/2013
56	NivolumabIBA 02/2024 - 01/2015
53	trametinibIBA 05/2024 - 11/2012
40	Biomarkers (Surrogate Marker)IBA 12/2023 - 05/2012
20	VemurafenibIBA 01/2018 - 03/2012
19	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2012
19	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 01/2013
16	AntibodiesIBA 01/2024 - 09/2013
14	LigandsIBA 01/2023 - 07/2015
13	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 06/2024 - 03/2016
12	B7-H1 AntigenIBA 01/2023 - 03/2014
10	SteroidsIBA 05/2024 - 10/2014
10	RNA (Ribonucleic Acid)IBA 04/2024 - 01/2020
9	Circulating Tumor DNAIBA 01/2022 - 12/2015
9	Dacarbazine (DIC)FDA LinkGeneric 11/2020 - 01/2012
9	Phosphotransferases (Kinase)IBA 01/2020 - 12/2014
8	Formaldehyde (Formol)FDA Link 01/2023 - 01/2013
8	Mitogen-Activated Protein KinasesIBA 10/2022 - 01/2012
7	relatlimabIBA 10/2023 - 01/2022
7	ParaffinIBA 01/2023 - 01/2013
7	CytokinesIBA 01/2023 - 03/2014
6	Programmed Cell Death 1 ReceptorIBA 09/2023 - 11/2018
6	AntigensIBA 01/2023 - 11/2020
5	Monoclonal AntibodiesIBA 01/2022 - 01/2017
5	CateninsIBA 12/2017 - 01/2014
5	Proto-Oncogene Proteins B-rafIBA 09/2015 - 09/2013
4	spartalizumabIBA 01/2023 - 10/2020
4	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2022 - 10/2014
4	Cell-Free Nucleic AcidsIBA 11/2020 - 09/2013
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 02/2024 - 10/2014
3	Messenger RNA (mRNA)IBA 01/2024 - 01/2018
3	bempegaldesleukinIBA 10/2023 - 10/2020
3	atezolizumabIBA 01/2023 - 01/2018
3	ChemokinesIBA 01/2023 - 03/2014
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2019
3	MART-1 AntigenIBA 12/2021 - 09/2013
3	GlucocorticoidsIBA 11/2021 - 11/2020
3	CTLA-4 AntigenIBA 10/2020 - 03/2014
3	EnzymesIBA 01/2019 - 01/2017
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2017 - 03/2014
2	Interferon-gamma (Interferon, gamma)IBA 04/2024 - 12/2023
2	Acetaminophen (Paracetamol)FDA LinkGeneric 02/2024 - 10/2014
2	binimetinibIBA 01/2024 - 01/2017
2	Bispecific AntibodiesIBA 12/2023 - 10/2022
2	Metformin (Glucophage)FDA LinkGeneric 01/2023 - 01/2020
2	cobimetinibIBA 01/2023 - 01/2018
2	talimogene laherparepvecIBA 01/2023 - 09/2017
2	Differentiation AntigensIBA 01/2023 - 12/2020
2	Immunoglobulin G (IgG)IBA 01/2023 - 01/2021
2	Leucine (L-Leucine)FDA Link 12/2022 - 11/2022
2	Dihydrotachysterol (AT 10)IBA 11/2022 - 01/2021
2	Lipase (Acid Lipase)FDA Link 11/2022 - 11/2012
2	cyclopropapyrroloindoleIBA 10/2022 - 01/2022
2	Interleukin-2 (IL2)IBA 01/2022 - 06/2014

Therapy/Procedure

220	Therapeutics 06/2024 - 04/2011
106	Immunotherapy 04/2024 - 09/2012
19	Drug Therapy (Chemotherapy) 08/2023 - 01/2012
12	Radiotherapy 10/2023 - 01/2013
11	Neoadjuvant Therapy 05/2024 - 01/2019
10	Lymph Node Excision (Lymph Node Dissection) 05/2024 - 01/2019
5	Aftercare (After-Treatment) 01/2023 - 03/2012
3	Retreatment 01/2023 - 01/2018
2	Salvage Therapy 11/2023 - 01/2023